J.W. Cole Advisors’s Plus Therapeutics PSTV Stock Holding History

J.W. Cole Advisors’s Portfolio PSTV Stock Details PSTV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-400	Closed	-$5.12K	–	1309
2025 Q4	$5.12K	Buy	+400	New	+$6.03K	﹤0.01%	1453

Other funds holding PSTV

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

J.W. Cole Advisors's PSTV Position: Q1 2026 in Review

J.W. Cole Advisors sold out of Plus Therapeutics (PSTV) in Q1 2026, closing a stake of 400 shares — an estimated $5.12K sold.

J.W. Cole Advisors first reported a position in PSTV in Q4 2025 and held it in 1 quarter. The position peaked at $5.12K in Q4 2025. 23 funds tracked by Wall St. Rank hold PSTV as of Q1 2026.

J.W. Cole Advisors reported no remaining Plus Therapeutics position as of Q1 2026 after selling out during the quarter.
J.W. Cole Advisors sold 400 Plus Therapeutics shares in Q1 2026, an estimated $5.12K.
J.W. Cole Advisors first reported a position in Plus Therapeutics in Q4 2025 and held it in 1 quarter.
J.W. Cole Advisors's Plus Therapeutics position peaked at $5.12K in Q4 2025.
23 funds tracked by Wall St. Rank held Plus Therapeutics as of Q1 2026.

Based on J.W. Cole Advisors's 13F filing for Q1 2026, filed 23 Apr 2026.